Replies to post #87893 on Biotech Values

[rkrw]

Teva is funding it all.

As far as risk, that describes most of biotech!

[wallstarb]

Thats why I think they will raise more cash to throw at the otehr 2 compunds they have licensed from ISIS. They don't have a ton of $$$ when you take out the $30m earmarked for OGX-011.

I'm not sure how much of that can be put towards SG&A which may overlap the programs but $20 - $25m won't last long taking 2 compounds through phase1/2 - since TEVA is now takign over OGX-011 they need something to justify their paychecks.